tiprankstipranks
Advertisement
Advertisement

ZVRA Stock Latest News

Zevra Therapeutics chief medical officer to step down
The FlyZevra Therapeutics chief medical officer to step down
3d ago
ZVRA
Zevra Therapeutics price target raised to $35 from $25 at Maxim
PremiumThe Fly
Zevra Therapeutics price target raised to $35 from $25 at Maxim
4d ago
ZVRA
Zevra Therapeutics price target raised to $29 from $25 at Guggenheim
PremiumThe Fly
Zevra Therapeutics price target raised to $29 from $25 at Guggenheim
4d ago
ZVRA
Zevra Therapeutics price target raised to $27 from $23 at BTIG
PremiumThe Fly
Zevra Therapeutics price target raised to $27 from $23 at BTIG
5d ago
ZVRA
Zevra Therapeutics price target raised to $29 from $24 at Canaccord
PremiumThe Fly
Zevra Therapeutics price target raised to $29 from $24 at Canaccord
5d ago
ZVRA
Analyst Reiterates Buy on Zevra as Extended MIPLYFFA Patent Protection and Cash Generation Support Unchanged $26 Price Target
PremiumRatingsAnalyst Reiterates Buy on Zevra as Extended MIPLYFFA Patent Protection and Cash Generation Support Unchanged $26 Price Target
5d ago
ZVRA
Zevra Therapeutics price target raised to $25 from $18 at Citizens
Premium
The Fly
Zevra Therapeutics price target raised to $25 from $18 at Citizens
6d ago
ZVRA
Extended U.S. Patent Protection for Miplyffa Underpins Buy Rating and Long-Term Upside for Zevra
Premium
Ratings
Extended U.S. Patent Protection for Miplyffa Underpins Buy Rating and Long-Term Upside for Zevra
6d ago
ZVRA
Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald
PremiumThe Fly
Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald
6d ago
ZVRA
Zevra Therapeutics announces Orange Book listing of Miplyffa patent
PremiumThe Fly
Zevra Therapeutics announces Orange Book listing of Miplyffa patent
6d ago
ZVRA
Zevra Investors Reelect Directors, Reject Governance Structure Change
PremiumCompany Announcements
Zevra Investors Reelect Directors, Reject Governance Structure Change
9d ago
8K
ZVRA
Zevra Therapeutics Earnings Call Highlights Growth Pivot
PremiumCompany Announcements
Zevra Therapeutics Earnings Call Highlights Growth Pivot
1M ago
ZVRA
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim
PremiumThe FlyZevra Therapeutics price target raised to $25 from $23 at Guggenheim
1M ago
ZVRA
Analyst Reiterates Buy on Zevra, Keeps DCF-Based Price Target Unchanged at $24 Amid Robust Miplyffa Performance and Pipeline Optionality
Premium
Ratings
Analyst Reiterates Buy on Zevra, Keeps DCF-Based Price Target Unchanged at $24 Amid Robust Miplyffa Performance and Pipeline Optionality
1M ago
ZVRA
Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Execution, Debt-Free Balance Sheet Support Upside with Price Target Maintained at $26
Premium
Ratings
Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Execution, Debt-Free Balance Sheet Support Upside with Price Target Maintained at $26
1M ago
ZVRA
Zevra Therapeutics reports Q1 EPS 60c, consensus 8c
PremiumThe Fly
Zevra Therapeutics reports Q1 EPS 60c, consensus 8c
1M ago
ZVRA
Zevra Therapeutics Earnings Call Signals Profitable Turn
PremiumCompany Announcements
Zevra Therapeutics Earnings Call Signals Profitable Turn
2M ago
ZVRA
Zevra Pharmaceuticals: SDX Monetization, Debt Elimination, and Miplyffa Ramp Support Buy Rating
PremiumRatings
Zevra Pharmaceuticals: SDX Monetization, Debt Elimination, and Miplyffa Ramp Support Buy Rating
3M ago
ZVRA
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
3M ago
MOLN
SVCO
Zevra Sells SDX Portfolio and Resolves Litigation
PremiumCompany AnnouncementsZevra Sells SDX Portfolio and Resolves Litigation
3M ago
8K
ZVRA
Zevra Therapeutics sells SDX portfolio to Commave for $50M
Premium
The Fly
Zevra Therapeutics sells SDX portfolio to Commave for $50M
3M ago
ZVRA
Zevra Therapeutics initiated with a Buy at BTIG
Premium
The Fly
Zevra Therapeutics initiated with a Buy at BTIG
3M ago
ZVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >